GlassScriptPhysician profile
Albert G Caruana
NPI 1154527851
$17,580.82
in general payments reported to CMS, 2019-2025
29 companies · $3,435 in 2025
The $3,435 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,252 · 2021: $4,769 · 2022: $2,394 · 2023: $1,502 · 2024: $3,069 · 2025: $3,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,830 · Travel and Lodging: $1,089 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,829.73 |
| Travel and Lodging | $1,088.77 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,324.26 | 2019-2025 | Lensx, Clareon, Eysuvis |
| Sight Sciences, INC. | $4,076.09 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $1,485.00 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Mallinckrodt Hospital Products INC. | $933.61 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $789.35 | 2022-2025 | Miebo, Envista Mx60 Iol, Vyzulta |
| Sun Pharmaceutical Industries INC. | $634.83 | 2019-2024 | Cequa |
| Allergan, INC. | $611.69 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $404.68 | 2019-2021 | |
| Glaukos Corporation | $385.26 | 2019-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Idose |
| Dompe US, INC. | $371.84 | 2020-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $334.85 | 2019-2025 | Tecnis Iol |
| Eyevance Pharmaceuticals LLC | $298.02 | 2019-2021 | |
| New World Medical,INC. | $294.85 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Kala Pharmaceuticals, INC. | $260.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $195.35 | 2020-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $190.04 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $164.91 | 2022-2025 | Tyrvaya, Ryzumvi |
| Akorn, INC. | $142.55 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $132.48 | 2024-2025 | Xdemvy |
| Rxsight INC | $100.46 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $87.80 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $75.68 | 2019-2021 | |
| Biotissue Holdings INC. | $63.08 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $48.34 | 2024-2025 | Omidria, Rayone Emv, Rayone Spheric |
| Shire North American Group INC | $47.47 | 2019 | |
| Ani Pharmaceuticals, INC. | $46.28 | 2025 | Purified Cortrophin Gel |
| Thea Pharma INC. | $38.26 | 2023-2025 | Iyuzeh |
| Topcon Healthcare, INC. | $28.10 | 2023 | |
| Ocular Therapeutix, INC. | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Caruana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.